Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revamilast in chronic persistent asthma (phase II, 12-week, randomized, double-blind, placebo-controlled)
2011-000270-57Phase 2Completed
- Sponsor
- Glenmark Pharmaceuticals SA
- Start
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, triple-blind trial in asthma comparing Revamilast arm(s) with Placebo arm (2 arms). Primary endpoint: Change in morning pre-dose FEV1 from baseline to day 84. Started Feb 2011; status: completed.
02
Drugs
revamilast
03
Conditions
asthma
Beyond the preview
Go deeper on 2011-000270-57.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000270-57.